Cancer immunotherapy .net
Information for doctors 2
Skip data for vets and go to information for doctors 3
Human cancers sensitive to IL-2
      (usually about 50-70% objective responses)

Lung metastases of renal cell carcinoma
Huland et al. (1994) J. Cancer Res. Clin. Oncol. 120:221
Huland et al. (1997) Cancer J. Sci. Am..3 Suppl.1 , S68
Huland & Heinzer (2003) Curr. Op. Urol. 13, 451
Huland et al. (2003) Folia Biol (Praha) 49,183
Huland & Heinzer (2004) Curr. Op. Urol. 14, 239
Huland et al. (2004) Urologe A

Recurrent superficial bladder carcinoma
Tubaro et al. (1995) Eur. Urol. 28, 297
Den Otter et al. (1998) J. Urol. 159, 1183
Grasso et al. (2001) J. Immunother. 24, 184

Nasopharyngeal carcinoma stage III-IV

Jacobs et al. (2005) Cancer Immunol. Immunother. 54, 792

Metastasized melanoma
Radny et al. (2003) Br. J. Cancer 89: 1620-6
Pfoehler et al. (2004) Hautzartz 55:171-5
Green (2007) Br.J.Dermatol. 156:337-4

Human cancer being studied

Therapeutic effect is being studied means less than 10 cases are evaluated, some with positive results

Krastev et al. (2001) Cancer Immunol. Immunother. 50, 22

Hepatocellular carcinoma

Krastev et al. (2003) Hepatogastroenterology 50, 1647
Krastev et al. (2005) World J. Gastroenterol. 11, 5525

Colorectal carcinom
Krastev et al. (2005) World J. Gastroenterol. 11, 552

Krastev et al. (2005) World J. Gastroenterol. 11, 552
Information for doctors
Information for patients
I want to support this research or  more information on the EPTI fund supporting this research
Interleukin-2 (IL-2)
Mechanism of IL-2 therapy of cancer

Cancers sensitive to IL-2

Local IL-2 and other therapies:
Surgery and IL-2
Radiotherapy and IL-2
Chemotherapy and IL-2

Our research group by specialism and by research center

I want to co-operate (doctors)

Frequently Asked Questions (FAQs)
Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de Tumour Immunologie. Stichting EPTI, IJselstein, The Netherlands